G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company has worldwide commercial rights to three clinical-stage oncology programs. Trilaciclib is a first-in-class FDA-designated “Breakthrough Therapy” designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant (G1T48), a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer.